Transimmune AG has been awarded a $5 million investment from the Bill & Melinda Gates Strategic Investment Fund that will be used to leverage Transimmune’s physiologically induced dendritic cells (phDCs) to enhance the potency of mRNA vaccines in infectious diseases. The initial focus will be on a therapeutic vaccine for people with HIV.
Spybiotech Ltd. has filed a clinical trial application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate SPYVLP-01, a vaccine targeting human cytomegalovirus (CMV) using its hepatitis B virus-like-particle platform technology.